Type 2 Diabetes News and Research

Latest Type 2 Diabetes News and Research

$3 million grant to aid minorities with uncontrolled diabetes

Researchers at the University of Illinois at Chicago's Institute for Health Research and Policy and College of Medicine have received a $3 million federal grant to improve diabetes management in minority patients.

28 Jul 2011

Amylin, Lilly and Alkermes submit reply to FDA complete response letter for BYDUREON

Amylin Pharmaceuticals, Inc., Eli Lilly and Company and Alkermes, Inc. today announced that the companies have submitted their reply to a complete response letter issued in October 2010 by the U.S. Food and Drug Administration (FDA) regarding BYDUREON™ (exenatide extended-release for injectable suspension), an investigational medication for type 2 diabetes.

28 Jul 2011

Relative muscle mass inversely linked with insulin resistance and pre-diabetes

A recent study accepted for publication in The Endocrine Society's Journal of Clinical Endocrinology & Metabolism (JCEM) found that the greater an individual's total muscle mass, the lower the person's risk of having insulin resistance, the major precursor of type 2 diabetes.

28 Jul 2011

Ironwood licenses worldwide rights to Depomed's Acuform drug delivery technology

Ironwood Pharmaceuticals, Inc. and Depomed, Inc. today announced that Ironwood has licensed worldwide rights to utilize Depomed's Acuform gastric retentive drug delivery technology for an Ironwood early stage development program, continuing Ironwood's efforts to augment its development pipeline beyond linaclotide.

28 Jul 2011

Menopause has no additional effect on risk for diabetes

Menopause has little to no impact on whether women become more susceptible to diabetes, according to a one-of-a-kind study.

27 Jul 2011

Type 2 diabetes and obesity in pregnancy is a daunting duo: New research

Type 2 diabetes and obesity in pregnancy is a daunting duo, according to new research published this month in The Journal of Maternal-Fetal and Neonatal Medicine. The study shows that both conditions independently contribute to higher risks, opening the door to a wide range of pregnancy, delivery and newborn complications.

26 Jul 2011

Women & Infants creates fully integrated center for high-risk pregnancy

Every pregnancy deserves special treatment. But when a woman with a normal pregnancy has a complication or a woman with a medical issue becomes pregnant, she needs highly specialized care.

26 Jul 2011

Takeda resubmits alogliptin and fixed-dose combination therapy NDA to FDA

Takeda Pharmaceutical Company Limited announced today that Takeda Global Research & Development Center, Inc., resubmitted two New Drug Applications to the United States Food and Drug Administration for alogliptin and the fixed-dose combination therapy alogliptin/pioglitazone, which combines alogliptin with pioglitazone in a single tablet.

26 Jul 2011

Australian TGA approves GI Dynamics EndoBarrier Gastrointestinal Liner for type 2 diabetes and obesity

GI Dynamics, Inc., a company focused on the development and commercialization of effective, non-surgical approaches for the treatment of type 2 diabetes and obesity, today announced that the Australian Therapeutic Goods Administration (TGA) has approved the EndoBarrier® Gastrointestinal Liner for inclusion on the Australian Register of Therapeutic Goods (ARTG).

25 Jul 2011

Valeritas' V-Go Disposable Insulin Delivery Device receives CE Mark approval

Valeritas, Inc., a medical technology company focused on the development and commercialization of innovative drug delivery solutions, announced today it received CE Mark approval for its V-Go Disposable Insulin Delivery Device as well as ISO 13485: 2003 Quality Management System Certification.

25 Jul 2011

Advancements in use of zinc finger nucleases to produce genetically modified pigs

Sangamo BioSciences, Inc. announced the publication of a study demonstrating the use of zinc finger nucleases (ZFNs) to produce genetically modified pigs. The study, which was published in the Proceedings of the National Academy of Sciences (PNAS), represents a significant advancement in the development of improved, less immunogenic animal tissue as a source for transplant into humans.

22 Jul 2011

Isis commences ISIS-PTP1BRx Phase 1 study in type 2 diabetes

Isis Pharmaceuticals, Inc. announced today that it has initiated a Phase 1 clinical study for ISIS-PTP1BRx, an antisense drug for the treatment of type 2 diabetes targeting protein tyrosine phosphatase-1B, PTP-1B.

21 Jul 2011

Diabetes trends in Alberta

The Alberta Diabetes Surveillance System was created in 2006 in partnership between Alberta Health and Wellness and the Institute of Health Economics. Led by Jeff Johnson in the University of Alberta's School of Public Health, the group has been identifying trends in diabetes, its associated health conditions and monitoring trends in accessing health-care services and has published a comprehensive report called a Diabetes Atlas every two years.

21 Jul 2011

Promising compounds for new anti-obesity drugs

Though it generally is known that obesity dramatically increases the risk for type 2 diabetes, the biological mechanisms for that connection still are unclear.

21 Jul 2011

Channel Swim Relay event aims to raise money for JDRF

Six swimmers congregate along the Dover coastline today, to participate in a 17-hour relay swim across the English Channel to France. The relay event, sponsored by Animas,aims to raise money for the Juvenile Diabetes Research Foundation (JDRF) and celebrate people with diabetes performing at their best.

21 Jul 2011

FDA panel votes against novel diabetes drug citing adverse effects

An advisory panel for the US Food and Drugs Administration voted 9-6 that the FDA should not yet approve dapagliflozin, a new type of diabetes drug that makes the body dump sugar and lose weight. Signals of possible liver damage and of breast and bladder cancer worried the experts.

20 Jul 2011

Diabetes gene linked to Alzheimer’s

Researchers from Mount Sinai School of Medicine have identified a gene that causes diabetes kills nerve cells in the brain, possibly resulting in Alzheimer’s disease.

20 Jul 2011

VIVUS to present topiramate exposure, birth defect data at IEC

VIVUS, Inc. today announced that on August 31, 2011, during the late breaking poster session at the 29th International Epilepsy Congress in Rome, Italy, Dr. Alison Pack, Associate Professor of Clinical Neurology, Department of Neurology, Columbia University Medical Center, will present the results of a retrospective study of medical claims data on oral clefts (OC) and major congenital malformations (MCMs) associated with in utero topiramate exposure.

20 Jul 2011

Investigational compound dapagliflozin receives negative recommendation from FDA Advisory Committee

Bristol-Myers Squibb Company and AstraZeneca today reported the outcome of the U.S. Food and Drug Administration's (FDA) Endocrinologic and Metabolic Drugs Advisory Committee meeting on the New Drug Application for the investigational compound dapagliflozin.

20 Jul 2011

Obesity in kids reaches extreme levels

According to a Victoria's top childhood obesity experts, toddlers are becoming so obese they need hospital treatment and 10-year-olds so overweight they risk heart disease. This comes from Dr Matt Sabin, co-head of the Royal Children's Hospital weight management clinic who labeled Victoria's obesity epidemic as extreme. He said he often saw three-year-olds weighing 35kg - more than double their healthy weight - and 15-year-olds tipping the scales at up to 200kg.

18 Jul 2011